Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Imaging for Surveillance of Oral Potentially Malignant Disorders
NCT02790853Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- May 2028
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of proflavine hemisulphate in oral potentially malignant disorder (OPMD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Detection of high grade dysplasia and carcinoma at 2 years. Started May 2016; status: active, not recruiting.
02
Drugs
proflavine hemisulphate
03
Conditions
oral potentially malignant disorder (OPMD)
Beyond the preview
Go deeper on NCT02790853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790853.